Altered GH-IGF-1 Axis in Severe Obese Subjects is Reversed after Bariatric Surgery-Induced Weight Loss and Related with Low-Grade Chronic Inflammation.
Paula Juiz-ValiñaLara Pena-BelloMaria CordidoElena Outeiriño-BlancoSonia PértegaBárbara María Varela-RodríguezMaria Jesus Garcia-BraoEnrique MenaSusana Sangiao-AlvarellosFernando CordidoPublished in: Journal of clinical medicine (2020)
Endocrine disorders are common in obesity, including altered somatotropic axis. Obesity is characterized by reduced growth hormone (GH) secretion, although the insulin-like growth factor-1 (IGF-1) values are controversial. The aim of this study was to evaluate the effect of weight loss after bariatric surgery in the GH-IGF-1 axis in extreme obesity, in order to investigate IGF-1 values and the mechanism responsible for the alteration of the GH-IGF-1 axis in obesity. We performed an interventional trial in morbidly obese patients who underwent bariatric surgery. We included 116 patients (97 women) and 41 controls (30 women). The primary endpoint was circulating GH and IGF-1 values. Circulating IGF-1 values were lower in the obese patients than in the controls. Circulating GH and IGF-1 values increased significantly over time after surgery. Post-surgery changes in IGF-1 and GH values were significantly negatively correlated with changes in C-reactive protein (CRP) and free T4 values. After adjusting for preoperative body mass index (BMI), free T4 and CRP in a multivariate model, only CRP was independently associated with IGF-1 values in the follow-up. In summary, severe obesity is characterized by a functional hyposomatotropism at central and peripheral level that is progressively reversible with weight loss, and low-grade chronic inflammation could be the principal mediator.
Keyphrases
- growth hormone
- weight loss
- bariatric surgery
- obese patients
- roux en y gastric bypass
- low grade
- gastric bypass
- weight gain
- body mass index
- metabolic syndrome
- insulin resistance
- type diabetes
- high grade
- oxidative stress
- glycemic control
- pregnant women
- randomized controlled trial
- drug induced
- polycystic ovary syndrome
- patients undergoing
- endothelial cells
- clinical trial
- high glucose
- cell proliferation
- prognostic factors
- early onset
- patient reported outcomes
- open label
- adipose tissue
- patient reported